Vector Science begins pharma-grade peptide production at first LyoGenesis suite, targets 55,000 vials a month

• Vector Science & Therapeutics began pharma-grade peptide production at its first LyoGenesis Manufacturing suite, starting fulfillment of existing nine-peptide orders this month.
• Initial capacity runs about 55,000 vials per month, fully pre-sold; three larger suites are slated to start in the latter half of September 2026.
• Combined monthly capacity is targeted at up to 800,000 vials once all four suites are online.
• Output is expected to scale to about 200,000 vials per month within three months; a major customer indicated potential commitments at that level.
• Management expects about an 80% margin per sale after production costs, citing premium pricing for pharma-grade peptides.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vector Science and Therapeutics Corp. published the original content used to generate this news brief via CNW (Ref. ID: 202608240730CANADANWCANADAPR_C1532) on August 24, 2026, and is solely responsible for the information contained therein.